Cencora said revenue for the quarter ended December 31, 2024 increased $9.2 billion, or 12.8%, from the prior year quarter. U.S. Healthcare Solutions revenue grew $8.8 billion, or 13.6%, and the company cited increased sales of GLP-1 products of $3.2 billion, or 53.0%.

10-QQuarterly reportFiled Feb 5, 2025Period of report Dec 31, 2024Summary published (UTC) Oct 10, 2026

Key points

AI summary

Cencora said revenue for the quarter ended December 31, 2024 increased $9.2 billion, or 12.8%, from the prior year quarter. U.S. Healthcare Solutions revenue grew $8.8 billion, or 13.6%, and the company cited increased sales of GLP-1 products of $3.2 billion, or 53.0%.
The company said gross profit increased $89.2 million, or 3.6%, from the prior year quarter. U.S. Healthcare Solutions' gross profit margin was 2.28%, a decline of 13 basis points, and the company cited higher sales of GLP-1 products, which have lower gross profit margins, and lower sales of COVID vaccines, which have higher gross profit margins, as factors.
Cencora said on January 2, 2025 it acquired approximately 85% of Retina Consultants of America (RCA), with cash outlay at closing of $4.4 billion. The purchase price is subject to customary post-closing adjustment, and the company said the agreement provides for potential contingent consideration of up to $500 million in fiscal 2027 and fiscal 2028, subject to the successful completion of certain predefined business objectives.
Cencora said operating activities used $2.7 billion of cash in the quarter ended December 31, 2024, compared to cash provided by operations of $0.9 billion in the prior year quarter. The company cited an increase in inventories of $1.7 billion, an increase in accounts receivable of $974.3 million, and a decrease in accounts payable of $654.2 million as principal items.

Key figures

Quarter ended December 31, 2024

Revenue: $81.5B
Operating income: $706M
Net income: $489M
EPS: $2.50
Gross profit: $2.6B
Operating cash flow: −$2.7B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Cencora Quarterly Revenue Up 12.8%

Cencora said revenue for the quarter ended December 31, 2024 increased $9.2 billion, or 12.8%, from the prior year quarter. U.S. Healthcare Solutions revenue grew $8.8 billion, or 13.6%, and the company cited increased sales of GLP-1 products of $3.2 billion, or 53.0%.

Source · Based on the MD&A text of the filing

Gross Profit Rises 3.6%, Margin Down 13 basis points

The company said gross profit increased $89.2 million, or 3.6%, from the prior year quarter. U.S. Healthcare Solutions' gross profit margin was 2.28%, a decline of 13 basis points, and the company cited higher sales of GLP-1 products, which have lower gross profit margins, and lower sales of COVID vaccines, which have higher gross profit margins, as factors.

Source · Based on the MD&A text of the filing

RCA Acquisition of 85% Stake Closes for $4.4 billion in Cash

Cencora said on January 2, 2025 it acquired approximately 85% of Retina Consultants of America (RCA), with cash outlay at closing of $4.4 billion. The purchase price is subject to customary post-closing adjustment, and the company said the agreement provides for potential contingent consideration of up to $500 million in fiscal 2027 and fiscal 2028, subject to the successful completion of certain predefined business objectives.

Source · Based on the MD&A text of the filing

Quarterly Operating Activities Used $2.7 billion in Cash

Cencora said operating activities used $2.7 billion of cash in the quarter ended December 31, 2024, compared to cash provided by operations of $0.9 billion in the prior year quarter. The company cited an increase in inventories of $1.7 billion, an increase in accounts receivable of $974.3 million, and a decrease in accounts payable of $654.2 million as principal items.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.